Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.
Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.
![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
